- Ticker
- ABEO
- Price
- 2.40
- Stock movement down
- -0.05 (-2.04%)
- Company name
- Abeona Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Marktkapitalisierung
- 41.22M
- Ent-Wert
- 58.84M
- Preis/Umsatz
- 9.48
- Preis/Buch
- 2.67
- Div-Ertrag
- -
- Div Wachstum
- -
- Wachstumsjahre
- -
- FCF-Ausschüttung
- -
- Nachlaufendes KGV
- -
- Forward P/E
- -
- PEG
- -
- EPS-Wachstum
- -
- 1 Jahr Rückkehr
- 727.59%
- 3-Jahres-Rendite
- 4.06%
- 5-Jahres-Rendite
- -30.24%
- 10-Jahres-Rendite
- -20.25%
Zuletzt aktualisiert: 2023-03-22
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
29. März 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
1. Dezember 2022
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABEO keine Dividenden ausschüttet
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
14. November 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3. November 2022
iO Charts is a Seeking Alpha partner
BEWERTUNG
Bewertungskennzahlen
Loading...
Daten zu den Bewertungsverhältnissen
| Nachlaufendes KGV | - |
| Preis zu OCF | - |
| Preis zu FCF | - |
| Preis zu EBITDA | - |
| EV zu EBITDA | - |
Bewertung (Umsatz/Buchwert)
Loading...
Bewertungsdaten (Umsatz/Buchwert)
| Preis zu Umsatz | 9.48 |
| Preis zum Buchen | 2.67 |
| EV zu Verkäufen | 13.54 |
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3. November 2022
iO Charts is a Seeking Alpha partner
Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
19. Oktober 2022
iO Charts is a Seeking Alpha partner
FINANZEN
Pro Aktie
Loading...
Angaben pro Aktie
| Aktuelle Anzahl der Aktien | 17.18M |
| EPS (TTM) | -13.28 |
| FCF pro Aktie (TTM) | -7.64 |
Gewinn- und Verlustrechnung
Loading...
Daten der Gewinn- und Verlustrechnung
| Umsatz (TTM) | 4.35M |
| Bruttogewinn (TTM) | 4.00M |
| Betriebsergebnis (TTM) | -84.63M |
| Reingewinn (TTM) | -85.25M |
| EPS (TTM) | -13.28 |
| EPS (1 Jahr vorwärts) | -1.79 |
Margen
Loading...
Daten zu den Margen
| Bruttomarge (TTM) | 91.95% |
| Operative Marge (TTM) | -1947.33% |
| Gewinnspanne (TTM) | -1961.64% |
Bilanz
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Bilanzdaten
| Bargeld | 5.73M |
| Nettoforderungen | 1.05M |
| Umlaufvermögen insgesamt | 25.50M |
| Goodwill | 0.00 |
| Immaterielle Vermögenswerte | 0.00 |
| Sachanlagen und Ausrüstung | 0.00 |
| Gesamtvermögen | 38.76M |
| Verbindlichkeiten aus Lieferungen und Leistungen | 1.75M |
| Kurz-/kurzfristige langfristige Schulden | 8.29M |
| Kurzfristige Verbindlichkeiten insgesamt | 12.60M |
| Verbindlichkeiten insgesamt | 23.35M |
| Aktionärseigenkapital | 15.41M |
| Netto-Sachanlagen | 15.41M |
Cashflow
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Cashflow-Daten
| Operativer Cashflow (TTM) | -46.16M |
| Investitionsausgaben (TTM) | 2.91M |
| Freier Cashflow (TTM) | -49.07M |
| Ausgeschüttete Dividenden (TTM) | 0.00 |
Finanzielle Erträge
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Daten zu Finanzerträgen
| Eigenkapitalrendite | -553.12% |
| Kapitalrendite | -219.95% |
| Rentabilität des investierten Kapitals | -495.00% |
| Cash Return on Invested Capital | -284.93% |
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
4. Oktober 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3. Oktober 2022
iO Charts is a Seeking Alpha partner
BESTANDSINFORMATIONEN
Aktienchart
Loading...
Daten zum Aktienkurs
| Öffnen Sie | 2.46 |
| Tageshöchststand | 2.49 |
| Tägliches Tief | 2.38 |
| Tägliches Volumen | 49K |
| Allzeithoch | 47188.00 |
| 1-Jahres-Analystenschätzung | 21.33 |
| Beta | 1.25 |
| EPS (TTM) | -13.28 |
| Dividende je Aktie | - |
| Ex-Div-Datum | 22 Jul 2022 |
| Nächstes Ergebnisdatum | 29 Mar 2023 |
Nachteiliges Potenzial
Loading...
Nachteilige potenzielle Daten
| ABEO | S&P500 | |
| Aktueller Preisrückgang vom Allzeithoch | -99.99% | -17.92% |
| Höchster Preisrückgang | -100.00% | -56.47% |
| Datum des höchsten Rückgangs | 17 Jun 2022 | 9 Mar 2009 |
| Durchschnittlicher Rückgang vom Höchststand | -92.06% | -11.51% |
| Durchschnittliche Zeit bis zum neuen Höchststand | 406 days | 13 days |
| Maximale Zeit bis zum neuen Höchststand | 7600 days | 1805 days |
The following slide deck was published by Abeona Therapeutics Inc.
17. August 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
11. August 2022
iO Charts is a Seeking Alpha partner
UNTERNEHMENSDATEN
Marketcap
41.22M
Kategorie Marktkapitalisierung
Small-cap
Beschreibung
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Mitarbeiter
90
Investor Relations
-
SEC-Anmeldungen
CEO
Joao Siffert
Land
USA
Stadt
New York
Art des Bestands
Common stock
CCC-Status
-
Häufigkeit der Ausschüttung
-
VERANSTALTUNGEN UND PRÄSENTATIONEN
VeranstaltungenPräsentationen
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
20. Juli 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
5. Juli 2022
iO Charts is a Seeking Alpha partner
DAS GESCHÄFT VERSTEHEN
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
19. Mai 2022
iO Charts is a Seeking Alpha partner
Abeona Therapeutics Inc.'s (ABEO) CEO Vishwas Seshadri on Q1 2022 Results - Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:NASDAQ:ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ETCompany ParticipantsVishwas Seshadri - Chief Executive OfficerJoseph Vazzano - Chief...
17. Mai 2022
iO Charts is a Seeking Alpha partner
UNTERNEHMENSNACHRICHTEN
Alle NachrichtenPresseveröffentlichungen
We can readily understand why investors are attracted to unprofitable companies. For example, although...
31. März 2023
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in ...
29. März 2023
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, A...
24. März 2023
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive d...
16. März 2023
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (AD...
14. März 2023
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
14. November 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
8. November 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
3. November 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
3. November 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
3. November 2022
Nächste Seite
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
17. Mai 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
13. Mai 2022
iO Charts is a Seeking Alpha partner